论文部分内容阅读
目的探讨急性脑梗死患者采用疏血通联合依达拉奉治疗的效果。方法 86例脑梗死患者,随机分为对照组和观察组,各43例。对照组患者采用疏血通治疗,观察组患者在对照组基础上联合依达拉奉治疗。对比两组患者临床治疗效果。结果观察组患者治疗总有效率为95.3%,高于对照组的81.4%,差异有统计学意义(P<0.05)。治疗后,两组患者美国国立卫生院卒中量表(NIHSS评分)均优于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血浆粘度、血细胞比容、纤维蛋白原等指标优于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。结论急性脑梗死患者采用疏血通联合依达拉奉治疗效果更理想,可有效改善患者神经功能,可推广应用。
Objective To investigate the effect of Shuxuetong combined with edaravone in patients with acute cerebral infarction. Methods 86 cases of cerebral infarction were randomly divided into control group and observation group, 43 cases in each group. Patients in the control group were treated with Shuxuetong, while patients in the observation group were treated with edaravone on the basis of the control group. The clinical effects of two groups were compared. Results The total effective rate of observation group was 95.3%, higher than that of control group (81.4%), the difference was statistically significant (P <0.05). After treatment, the National Institutes of Health Stroke Scale (NIHSS score) was better than before treatment in both groups, and the observation group was superior to the control group, the difference was statistically significant (P <0.05). After treatment, the indexes of plasma viscosity, hematocrit and fibrinogen in the two groups were better than those before treatment, and the observation group was better than the control group, the difference was statistically significant (P <0.05). Conclusion In patients with acute cerebral infarction, the combination of Shuxuetong and edaravone is more effective, which can effectively improve the neurological function of patients and can be popularized and applied.